Skip to Main Content

Paper Details

Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age â¿¥55 Years.
Transplant Cell Ther
1
2023
ALL, Acute Lymphoblastic Leukemia, B, B cell, B-ALL, B-lineage disease, Cyclophosphamide, GVHD, NRM, PTCy, Patients, Philadelphia, Philadelphia chromosome, Philadelphia chromosome-positive (Ph) ALL, T-ALL, Tyrosine, Tyrosine kinase, acute GVHD, acute lymphoblastic leukemia, chronic GVHD, cyclophosphamide, graft-versus-host disease, nonrelapse, patients
Author NameAffiliation
Mark J LevisNational Heart Lung and Blood Institute, University School of Medicine
Mark J LevisNational Heart Lung and Blood Institute, University School of Medicine
Christopher S HouriganNational Heart Lung and Blood Institute, University School of Medicine
Richard J JonesNational Heart Lung and Blood Institute, University School of Medicine
Richard J JonesNational Heart Lung and Blood Institute, University School of Medicine
  • 1 - 5

Datasets

Release 1.2